Market Newsdesk

• This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million
• Program progress and performance triggers $16.7 million contract option

GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, executed a contract modification for the second option period, valued at approximately $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga™ (ansuvimab-zykl). Ebanga™ is indicated for the treatment of infection caused by Zaire Ebola virus.

“We are delighted our continued collaboration with BARDA is advancing Ebanga™ development toward supplying treatment and ensuring communities are prepared against Ebola,” said Simon Lowry, M.D., chief medical officer, head of research and development, Emergent. “Ebola is a devastating infectious illness with limited treatment options. This important work reinforces Emergent’s leadership in developing solutions to address priority public health threats.”

The existing 10-year contract consists of a base period of performance with two option periods for advanced development valued at approximately $118 million, and option periods for procurement of Ebanga™ treatment over five years valued at up to $583 million. Under the terms of the contract, Emergent will complete activities to advance the development of Ebanga™ through post-licensure commitments. These activities include manufacturing scale-up, transferring manufacturing technology, and completing stability studies, as well as the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract 75A50123C00037.

About Ebanga™

Indication

Ebanga™ (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

Limitations of Use:

The efficacy of Ebanga™ has not been established for other species of the Ebolavirus and Marburgvirus genera.

Zaire ebolavirus can change over time, and factors such as emergence of resistance or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Zaire ebolavirus strains when deciding whether to use Ebanga™.

Important Safety Information

Hypersensitivity Reactions Including Infusion-Associated Events: Hypersensitivity reactions including infusion-associated events have been reported with Ebanga™. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following Ebanga™ infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of Ebanga™ immediately and administer appropriate emergency care.

Adverse reactions: The most frequently reported adverse events (≥ 5%) after administration of Ebanga™ were pyrexia (fever), tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills. The adverse event profile in adult and pediatric (birth to less than 18 years of age) subjects treated with Ebanga™ was similar.

U.S. Prescribing Information

The full Prescribing Information for Ebanga™ vaccine can be found here.

About Ebola Virus Disease

Orthoebolavirus zairense, referred to as Ebola virus disease (EVD) is severe and often fatal with case fatality rates ranging from 25% to 90%, and is transmitted via bodily fluids, zoonotic transmission, or contact with contaminated surfaces. The U.S. Department of Homeland Security has determined that EVD poses a material threat to national health security. To augment the U.S. government’s response capabilities, BARDA is pursuing advanced development, licensure, and procurement of therapeutics that can be deployed in outbreaks.

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the agreement with BARDA for the advanced development, manufacturing scale-up, and procurement of Ebanga™ treatment, including the potential exercise of option periods and any payments in connection therewith, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on Emergent’s current intentions, beliefs, and expectations regarding future events. Emergent cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Emergent’s expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Emergent does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause Emergent’s actual results to differ materially from those indicated by any forward-looking statements.

Readers should consider this cautionary statement, as well as the risk factors identified in Emergent’s periodic reports filed with the U.S. Securities and Exchange Commission when evaluating Emergent’s forward-looking statements.

Investor Contact:

Richard S. Lindahl
Executive Vice President, CFO
[email protected] 

Media Contact:

Assal Hellmer
Vice President, Communications
[email protected] 

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies 
for Cardiomyopathies

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data

Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated
Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025.

“2024 was a pivotal year for Tenaya, marked by important operational execution across our clinical-stage pipeline of gene therapy candidates with the potential to target and address the underlying drivers of heart disease,” said Faraz Ali, Chief Executive Officer of Tenaya. “As we enter 2025, we are eager to build on this momentum to accelerate enrollment and report on safety, biopsy and initial clinical endpoints from both our TN-201 and TN-401 programs throughout the year.”

Program Updates and Anticipated 2025 Milestones:

TN-201 – Gene Therapy for

MYBPC3

-Associated Hypertrophic Cardiomyopathy (HCM)

• Tenaya anticipates reporting additional data from Cohort 1 from the ongoing MyPEAK-1 Phase 1b/2 clinical trial of TN-201 for the potential treatment of MYBPC3-associated HCM in the first half of 2025. These data are expected to include safety and available assessments from the first three patients dosed, 52-week biopsy data for Patient 2, and baseline and post-dose biopsy data for Patient 3.
  • In December 2024, Tenaya announced initial interim data from Cohort 1, which showed TN-201 administered at the starting dose of 3E13 vg/kg was generally well-tolerated among the first three patients enrolled in the study. Among the first two patients, TN-201 achieved readily detectable vector DNA in the heart and evidence of transgene RNA expression. Serial biopsies at Week 8 and Week 52 for Patient 1 demonstrated increasing TN-201 mRNA and MyBP-C protein levels over time. Circulating biomarkers of cardiac muscle strain and injury remained largely stable, and certain clinical markers of disease showed stability or directional improvement in the first two individuals dosed, while other measures were not yet available, interpretable or mixed.
• The first patient received TN-201 at the 6E13 vg/kg dose in 2024 and enrollment in Cohort 2 of the MyPEAK-1 clinical trial is ongoing. Tenaya anticipates completing Cohort 2 enrollment in the first half of 2025 and providing initial Cohort 2 data and an update on Cohort 1 in the second half of 2025.
  • Cohort 2 of MyPEAK-1 expanded participant eligibility to include MYBPC3-associated HCM adults with the obstructive form of disease and patients without implantable cardioverter defibrillators (ICDs). All patients in Cohort 2 will receive a baseline biopsy, one post-dose and one at 52-weeks.
• Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second half of 2025.
  • The MyClimb study was initiated in 2021 to characterize the disease burden and progression of MYBPC3-associated HCM in patients under eighteen and has enrolled more than 200 participants.

TN-401 –Gene Therapy for

PKP2

-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

• Tenaya expects to complete enrollment of Cohort 1 of the RIDGE-1 Phase 1b clinical trial in the first half of 2025.
• Initial clinical data from the first cohort of patients receiving TN-401 at the 3E13 vg/kg dose, including safety and post-dose biopsy results, is expected in the second half of 2025.
  • TN-401 is Tenaya’s potential first-in-class AAV9-based gene therapy designed to deliver a functional PKP2 gene to heart muscle cells. The working PKP2 gene is intended to increase levels of PKP2, which are needed to maintain the structural integrity and cell-to-cell signaling of heart muscle cells.
  • In November 2024, Tenaya announced the dosing of the first patient in the RIDGE-1 trial.
• Tenaya anticipates activating its first ex-U.S. RIDGE-1 clinical site in the first half of 2025.
• Tenaya plans to present data from the non-interventional natural history and seroprevalence study (known as RIDGE) in the first half of 2025. To date, RIDGE has enrolled more than 100 PKP2-associated ARVC participants across 18 clinical sites.
  • Initial seroprevalence data from RIDGE presented in July 2024 indicated that antibodies to AAV9 were below the eligibility threshold for participation RIDGE-1.

Tenaya has established a rich portfolio of proprietary capabilities for targeted drug discovery and validation, and the design, production and targeted delivery of genetic medicines. In 2025, the company plans to continue research on promising targets for potential therapeutic utility and pursue platform enhancements that may further Tenaya’s ability to deliver on its mission of discovering and developing disease-modifying medicines for heart disease.

About 

MYBPC3

-Associated Hypertrophic Cardiomyopathy and TN-201 Gene Therapy

Variants in the Myosin Binding Protein C3 (MYBPC3) gene are the most common genetic cause of hypertrophic cardiomyopathy (HCM), accounting for approximately 20% of the overall HCM population, or 120,000 patients, in the United States alone.⁽¹⁾ TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. The U.S. Food and Drug Administration has granted TN-201 Fast Track, Orphan Drug and Rare Pediatric Drug Designations. TN-201 has also received orphan medicinal product designation from the European Commission.

About PKP2-associated ARVC and TN-401 Gene Therapy

TN-401 is being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC, also known as arrhythmogenic cardiomyopathy or ACM) caused by mutations in the plakophilin-2 (PKP2) gene. PKP2 gene mutations result in insufficient levels of critical proteins needed to maintain the structural integrity and cell-to-cell signaling of heart muscle cells. TN-401 gene replacement therapy is designed to deliver a functional PKP2 gene into heart muscle cells using an adeno associated virus serotype 9 (AAV9) capsid. In preclinical studies, the new, healthy PKP2 gene was successfully integrated into heart cells where it produced the missing protein to slow or even reverse the course of disease. TN-401 normalized heart rhythms, reversed disease progression and extended survival following a single dose in a knock-out genetic model of disease. The prevalence of PKP2-associated ARVC is estimated at more than 70,000 people in the U.S. alone.⁽²⁾ TN-401 has received Orphan Drug and Fast Track Designations from the FDA. TN-401 has also received orphan medicinal product designation from the European Commission.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com.

(1)   Sedaghat-Hemedani, et al., Clinical Research Cardiology, 2017
(2)   Peters, et a, Int J Cardiol 2004; McKenna, Nat Rev Card, 2021

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “continued,” “to be,” “anticipates,” “expected,” “plans,” “potential,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, statements regarding the advancement TN-201 and TN-401; planned timing to report additional Cohort 1 and Cohort 2 data from MyPEAK-1 and related focus of the data readouts; TN-201 clinical outcomes, which may materially change as patient enrollment continues or more patient data become available; the clinical, therapeutic and commercial potential of, and expectations regarding TN-201 and TN-401; expectations regarding completion of Cohort 1 enrollment for RIDGE-1 and ex-U.S. clinical site activation; planned timing for initial data from RIDGE-1 and related focus of the data readout; anticipated timing for completion of Cohort 2 enrollment for MyPEAK-1; planned timing to present data from MyClimb and RIDGE; statements regarding Tenaya’s research related activities; and statements made by Tenaya’s Chief Executive Officer. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of MyPEAK-1 and RIDGE-1 data at the referenced times; the timing and progress of MyPEAK-1 and RIDGE-1; the potential failure of TN-201 and TN-401 to demonstrate safety and/or efficacy in clinical testing; the potential for any MyPEAK-1 and/or RIDGE-1 clinical trial results to differ from preclinical, initial, interim, preliminary or expected results; Tenaya’s ability to enroll and maintain patients in clinical trials, including MyPEAK-1 and RIDGE-1; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company; availability of MyClimb and RIDGE data at the referenced time; Tenaya’s continuing compliance with applicable legal and regulatory requirements; Tenaya’s ability to raise any additional funding it will need to continue to pursue its product development plans; Tenaya’s reliance on third parties; Tenaya’s manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled “Risk Factors” in Tenaya’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, and other documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact

Michelle Corral
VP, Corporate Communications and Investor Relations
[email protected]

Investors

Anne-Marie Fields
Precision AQ (formerly Stern Investor Relations)
[email protected]

Media

Wendy Ryan
Ten Bridge Communications
[email protected]

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. The warrants will have an exercise price of $0.70 per share, will be exercisable immediately upon issuance, and will expire on the five year anniversary of the original issuance date. The shares of common stock (or pre-funded warrants) and the warrants comprising the units are immediately separable and will be issued separately in this offering. The closing of the offering is expected to occur on or about January 14, 2025, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-placement agent for the offering.

The gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $9.5 million. The Company intends to use the net proceeds from this offering to fund an installment towards the purchase price of the Wisconsin Fertility Institute, to redeem 4,000 shares of our Series C-2 preferred stock with a stated value of $4,000,000, towards outstanding debt obligations that are or will become payable upon completion of the offering and that we do not otherwise restructure or refinance, and the balance for clinical trials, product development, marketing, strengthening the corporate management team, working capital, general corporate purposes, and potential acquisitions of complementary businesses, technologies, or other assets.

The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-283872), which was declared effective by the Securities and Exchange Commission (the “SEC”) on January 13, 2025. The offering is being made only by means of a prospectus which forms a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at www.sec.gov and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About NAYA Biosciences

NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health. Our proven hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets and allowing for optimized return on investment by combining scalable, profitable commercial revenues with the upside of innovative clinical-stage therapeutics.

NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase 1/2a monotherapy trial in 2025, NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, NY-500, a PD-1 x VEGF bifunctional antibody for the treatment of HCC and other solid tumors, and NY-600 a PSMA x NKp46 bifunctional antibody for the treatment of metastatic Castration Resistant Prostate Cancer (mCRPC).

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We invoke the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. By their nature, all forward-looking statements are not statements of historical fact or guarantees of future performance and involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.  

NAYA Investor & Media Contact

Anna Baran-Djokovic
SVP, Investor Relations
+1-305-615-9162
[email protected]

MOUNT LAUREL, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) — J & J Snack Foods Corp. (NASDAQ: JJSF) announced today that it has scheduled a conference call and webcast to discuss its fiscal 2025 first quarter financial results on Tuesday, February 4, 2025, at 10:00 am Eastern time.

Conference call participants should pre-register by clicking on this Registration Link to receive the dial-in number and a personal PIN, which are required to access the conference call. Questions will be taken only from participants on the conference call.

A live webcast of the call can be accessed on the Company’s investor relations website at https://www.jjsnack.com/investors/. For the webcast, please allow 15 minutes to register, download and install any necessary software.

The Company expects to release its results for the 2025 fiscal first quarter ended December 28, 2024, at approximately 4:15 pm Eastern time on Monday, February 3, 2025.

About J & J Snack Foods Corp.

J & J Snack Foods Corp. (NASDAQ: JJSF) is a leader and innovator in the snack food and frozen beverage industry. For over fifty years, the company has specialized in delicious snack and beverage brands for the foodservice and retail segments, serving up fun across the U.S. market. J&J Snack Foods’ core brands include SUPERPRETZEL, the #1 soft pretzel brand, ICEE and SLUSH PUPPIE frozen beverages, and Dippin’ Dots, the original beaded ice cream. The company’s broad brand portfolio also includes LUIGI’S Real Italian Ice, MINUTE MAID* frozen ices, WHOLE FRUIT frozen fruit bars, DOGSTERS ice cream style treats for dogs, ¡Hola! Churros, THE FUNNEL CAKE FACTORY funnel cakes and fries, and bakery brands including MARY B’S, DADDY RAY’S, COUNTRY HOME BAKERS, and HILL & VALLEY. For more information, please visit http://www.jjsnack.com. *MINUTE MAID is a registered trademark of The Coca-Cola Company.

###

XIAMEN, China, Jan. 13, 2025 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT), today announced that it has entered into securities purchase agreements with several institutional investors to purchase an aggregate of 77,989,800 Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The Ordinary Shares are being sold at an offering price of $0.055 per share.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $4.3 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about January 14, 2025, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The Ordinary Shares are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-274893), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 26, 2024. The offering will be made only by means of a prospectus supplement that forms a part of such registration statement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the Ordinary Shares will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 895-3500.

About Blue Hat

Blue Hat was formerly a provider of communication services, as well as a producer, developer, and operator of AR interactive entertainment games, toys, educational materials and now primarily engage in commodity trading in China. For more information, please visit the Company’s investor relations website at http://ir.bluehatgroup.com. The Company routinely provides important information on its website.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company’s SEC filings. These risks and uncertainties could cause the Company’s actual results to differ materially from those indicated in its forward-looking statements.

Contact:

Blue Hat Interactive Entertainment Technology
Phone: +86 (592) 228-0010
Email: [email protected]